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Influenza vaccines must be updated regularly
because influenza viruses continuously acquire
mutations in antibody binding sites of hemagglutinin
(HA). The majority of H3N2 strains circulating in the
Northern Hemisphere during the 2014–2015 season
are antigenically mismatched to the A/Texas/50/
2012 H3N2 vaccine strain. Recent H3N2 strains
possess several newHAmutations, and it is unknown
which of thesemutations contribute to the 2014–2015
vaccine mismatch. Here, we use reverse genetics to
demonstrate that mutations in HA antigenic site B
are primarily responsible for the current mismatch.
Sera isolated from vaccinated humans and infected
ferrets and sheep had reduced hemagglutination
inhibition and in vitro neutralization titers against
reverse-genetics-derived viruses possessing muta-
tions in the HA antigenic site B. These data provide
an antigenic explanation for the low influenza vaccine
efficacy observed during the 2014–2015 influenza
season. Furthermore, our data support the World
Health Organization’s decision to update the H3N2
component of future vaccine formulations.
INTRODUCTION
Most neutralizing influenza antibodies (Abs) target the hemag-
glutinin (HA) glycoprotein. Seasonal influenza vaccines are de-
signed to elicit HA Abs; however, these vaccines are ineffective
when viruses acquire mutations in HA Ab binding sites (Yewdell,
2011). Mid-season influenza vaccine efficiency rates during the
2014–2015 Northern Hemisphere season are extremely low
(Flannery et al., 2015; Pebody et al., 2015), and recent H3N2
strains are antigenically distinct compared to the 2014–2015
A/Texas/50/2012 H3N2 vaccine strain (D’Mello et al., 2015).
The 2014–2015 H3N2 strains can be grouped into at least three
genetically distinct clades (Broberg et al., 2015). Viruses within
each genetic clade possess several shared and unique HA mu-tations, and it is currently unclear which of these mutations are
antigenically relevant.
H3 HAs have at least five distinct antigenic sites (sites A–E)
(Wiley et al., 1981). Seasonal influenza vaccine strains are
routinely chosen based on antigenic analyses that utilize antisera
prepared in ferrets (Sto¨hr et al., 2012). Koel and colleagues
recently demonstrated that most primary ferret Ab responses
to H3N2 viruses are heavily focused on H3 antigenic sites A
and B (Koel et al., 2013). Our studies and others have demon-
strated that prior H1N1 influenza exposures can influence the
specificity of Ab responses raised against new H1N1 influenza
strains (Hensley, 2014; Li et al., 2013b; Linderman et al., 2014).
We found that ferret antisera do not always recapitulate the
different types of H1N1 Ab specificities that are found in individ-
ual humans with vastly different pre-exposure histories. Human
Ab responses appear to be focused on antigenic site A of
someH3 strains (Abe et al., 2004) and on antigenic site B of other
H3 strains (Popova et al., 2012).
It is important to determine which HA residues are responsible
for the observed antigenic drift of 2014–2015 H3N2 strains. This
information can be useful for guiding the selection of viral strains
for future vaccine formulations. Here, we completed serological
assays using A/Texas/50/2012 H3N2 viruses engineered to have
specific HA mutations that are present in currently circulating
H3N2 strains.We find that mutations in H3 antigenic site B signif-
icantly decrease the binding of ferret, sheep, and human Abs
elicited by the A/Texas/50/2012 H3N2 vaccine strain. The World
Health Organization recently recommended that the H3 compo-
nent of seasonal influenza vaccines should be updated to
include A/Switzerland/9715293/2013-like strains (Anonymous,
2015). Our data support this recommendation, although we
note that the majority of currently circulating H3N2 strains have
a distinct antigenic site B compared to the A/Switzerland/
9715293/2013 strain.
RESULTS
2014–2015 H3N2 Viruses Possess Several HAMutations
The H3N2 component of the 2014–2015 influenza vaccine is
A/Texas/50/2012, which belongs to the 3C.1 HA genetic clade
(Broberg et al., 2015). During the 2014–2015 season, H3N2Cell Reports 12, 1–6, July 7, 2015 ª2015 The Authors 1
Table 1. HA Mutations in 2014–2015 H3N2 Viruses
Clades
3C.2a 3C.3 3C.3a
L3I
T128A T128A
A138S
R142G R142G
N144S
N145S N145S N145S
F159Y F159S
K160T
N225D N225D
Q311H
Shown are HA residues (H3 numbering) that differ between the A/Texas/
50/2012 H3N2 vaccine strain and most clade 3C.2a, 3C.3, and 3C.3a
viruses isolated during the 2014–2015 Northern Hemisphere influenza
season.strains belonging to the phylogenetic 3C.2a, 3C.3, and 3C.3a HA
clades predominated (Broberg et al., 2015). Compared to the
A/Texas/50/2012 strain, 3C.2a viruses possess HA differences
at L3I, N144S, N145S, F159Y, K160T, N225D, and Q311H,
3C.3 viruses possess HA differences at T128A, R142G, and
N145S, and 3C.3a viruses possess HA differences at T128A,
A138S, R142G, N145S, F159S, and N225D (Table 1). HA clade
3C.2a and 3C.3a viruses are antigenically distinct compared to
the A/Texas/50/2012 strain and the World Health Organization
has recommended that the H3N2 component should be updated
with an A/Switzerland/9715293/2013-like (HA 3C.3a) virus for
the Northern Hemisphere 2015–2016 vaccine (Anonymous,
2015).
Analyses of HA sequences deposited in the GISAID database
revealed that the majority of H3N2 viruses circulating in the
United States in the fall and winter of 2014 belong to HA clade
3C.2a (Figure 1A). To understand the antigenic basis for the
extremely poor H3N2 vaccine match during the 2014–2015 influ-
enza season, we created a panel of A/Texas/50/2012 viruses
that possessed HA mutations found in clade 3C.2a, 3C.3, and
3C.3a viruses (Table S1), and we completed antigenic analyses
using sera isolated from ferret, sheep, and humans exposed to
the A/Texas/50/2012 H3N2 vaccine strain (Tables 2 and 3). Our
mutant viral panel includes every mutation from Table 1 that is
located in the HA globular head (Figure 1B), with the exception
of the F159Y and K160Tmutations. Wewere able to successfully
rescue A/Texas/50/2012 viruses that possessed the F159Y and
K160T mutations, but these viruses failed to agglutinate red
blood cells and quickly mutated when propagated for antigenic
analyses. However, we were still able to assess the antigenic
relevance of mutations in this area of HA since our mutant panel
included a virus with the F159S HA mutation.
Ferrets and Sheep Infected with A/Texas/50/2012
Mount Abs against HA Antigenic Site B
We first completed hemagglutination-inhibition (HAI) assays
with our mutant A/Texas/50/2012 virus panel and sera collected2 Cell Reports 12, 1–6, July 7, 2015 ª2015 The Authorsfrom ferrets and sheep recovering from A/Texas/50/2012
infections (Table 2). As expected, anti-A/Texas/50/2012 Ab titers
were drastically decreased using the antigenically distinct
A/Switzerland/9715293/2013 clade 3C.3a virus. Strikingly, anti-
A/Texas/50/2012 Ab titers were decreased 4-fold in HAI assays
with viruses engineered to possess a single F159S HA mutation
(Table 2). Residue 159 is located in a highly exposed region of
antigenic site B of H3 HAs (Figure 1B). Other HA mutations had
more subtle effects on anti-A/Texas/50/2012 HAI titers. For
example, the A138S and N145S HA mutations each lead to
2-fold decreases in HAI titers.We previously showed that viruses
that bind to red blood cells with a high avidity can escape Abs in
HAI assays independently of antigenic change (Li et al., 2013a).
We found that A138S and N145S mutant viruses bound to red
blood cells with a higher avidity (Table S1), and the apparent
decreased HAI titers using these viruses likely result from this
increase in receptor binding avidity. We found that viruses
possessing the F159S mutation bound to red blood cells with a
decreased avidity (Table S1), and for this reason, we concluded
that reduced HAI titers using this virus were the result of a
genuine antigenic change.
To verify the antigenic relevance of the F159S HA mutation,
we completed additional direct Ab ELISA binding assays with
plates coated with viral like particles (VLPs) possessing
A/Texas/50/2012-WT HA or A/Texas/50/2012-F159S HA (Fig-
ure 1C). As a control, we coated plates with VLPs possessing
the antigenically distinct A/Port Chalmers/1/1973 HA (from
a 1973 H3 virus). Anti-sera isolated from ferrets infected
with A/Texas/50/2012 had reduced binding to VLPs possess-
ing A/Texas/50/2012-F159S HA compared to VLPs possessing
A/Texas/50/2012-WT HA (Figure 1C). We verified that equal
amounts of VLPs were used in these assays by completing
additional ELISA experiments with the F49 monoclonal anti-
body (mAb) that recognizes the conserved stalk region of H3
(Figure 1D). Collectively, these studies indicate that ferrets
and sheep mount Ab responses against an HA epitope
involving residue F159 following infection with A/Texas/50/
2012, and for this reason we focused the rest of antigenic an-
alyses on this region of HA.
Ferrets and Sheep Infected with A/Switzerland/
9715293/2013 Mount Ab Responses that Are Not
Focused against HA Epitope Involving Residue 159
We also completed HAI assays using our mutant viral panel and
anti-sera isolated from sheep infected with A/Switzerland/
9715293/2013 virus. Anti-sera isolated from A/Switzerland/
9715293/2013-infected animals reacted to all mutant A/Texas/
50/2012 viruses, including viruses that possessed the site B
F159S HA mutation (Table 2). Therefore, the F159S HA mutation
results in an asymmetrical antigenic change. These data are
important since A/Switzerland/9715293/2013 (an HA clade
3C.3a virus) has been chosen as the H3 component of 2015–
2016 seasonal vaccines, even though HA clade 3C.2a viruses
predominated toward the end of the 2014–2015 influenza sea-
son (Figure 1). Antigenic site B of HA clades 3C.3a and 3C.2a
viruses differ (Table 1), and future studies will need to be
completed to rigorously define the specificity of Abs elicited by
the A/Switzerland/9715293/2013 vaccine strain.
A B
C D
Figure 1. Genetically Distinct H3N2 Viruses
Circulated during 2014–2015 Influenza
Season in the United States
(A) HA sequences deposited on the GISAID data-
base were analyzed. All sequences deposited by
United States laboratories were included in the
analysis. Shown are the percentage of viruses that
belong to each HA clade (as defined in the text).
(B) The H3 structure (Protein Data Bank: 1HGG) is
shown with residues from Table 1 shown in yellow.
(C and D) ELISAs were completed with plates
coated with VLPs containing A/Texas/50/2012-
WT HA (A/TX/12-WT), A/Texas/50/2012-F159S
HA (A/TX/12-F159S), or A/Port Chalmers/1/1973
HA (A/PC/73). ELISAs were completed with
A/Texas/50/2012 ferret anti-sera (C) or the F49
mAb (D) that binds to a conserved region of the HA
stalk. Shown are mean and SEM of triplicate
samples. Data are representative of two indepen-
dent experiments.Anti-sera Isolated from Most Humans Vaccinated with
A/Texas/50/2012 Possess Abs against HA
Antigenic Site B
Next, we completed HAI assays using human sera collected pre-
and post-vaccination with the 2014–2015 seasonal influenza
vaccine, which contains the A/Texas/50/2012-like H3N2 strain.
We completed HAI assays using the A/Texas/50/2012 strain
and the A/Texas/50/2012 strain engineered to have the F159S
HA mutation. The A/Texas/50/2012 strain has been in seasonal
influenza vaccines since the 2013–2014 season and many indi-
viduals in our study had high A/Texas/50/2012 Ab titers that
were focused against antigenic site B prior to immunization (Ta-
ble 3). Following vaccination, most individuals either mounted
or maintained Abs that had reduced reactivity to viruses pos-
sessing the F159S HA mutation (Table 3). Importantly, we were
able to detect antigenic site B-specific Ab responses in humans
that represent a fairly large age range (21–50 years old). It is inter-Cell Reportsesting that some humans did not mount
Ab responses that were specific for
antigenic site B following vaccination.
Our previous studies suggest that influ-
enza pre-exposures can alter the immu-
nodominance of H1N1 Ab responses (Li
et al., 2013b; Linderman et al., 2014),
and it is possible that individuals who
do not mount site B-specific Ab re-
sponses have unique H3N2 pre-exposure
histories.
Anti-A/Texas/50/2012 Antigenic
Site B Abs Are Neutralizing
Next, we testedwhether anti-A/Texas/50/
2012 antigenic site B Abs identified in
ferrets and humans are neutralizing. We
completed in vitro neutralization assays
with A/Texas/50/2012 and A/Texas/50/
2012-F159S using sera samples isolated
from humans 21 days post-vaccination.We focused on samples that had the largest HAI differences
using A/Texas/50/2012 and A/Texas/50/2012-F159S viruses
(Table 3). We also completed in vitro neutralization assays with
antisera isolated from ferrets recovering from infection with
the A/Texas/50/2012 strain. Our in vitro neutralization results
mirrored our HAI results (Table S2). All seven human sera
samples and the ferret sera sample tested had dramatically
decreased in vitro neutralization titers using the A/Texas/50/
2012-F159S virus compared to the A/Texas/50/2012-WT virus
(Table S2).
DISCUSSION
Therewas a clear H3N2 vaccinemismatch during the 2014–2015
influenza season (Broberg et al., 2015; D’Mello et al., 2015; Flan-
nery et al., 2015; Pebody et al., 2015), and it is important to
identify specific HA mutations that have lead to this mismatch.12, 1–6, July 7, 2015 ª2015 The Authors 3
Table 2. Analyses of Ferret and Sheep Anti-sera Raised against the A/Texas/50/2012 and the A/Switzerland/9715293/13 Strains
Viruses
Sera
Ferret a-A/Texas/50/12 Sheep a-A/Texas/50/12 Sheep a-A/Switzerland/9715293/13
A/Texas/50/12-WT 960 10,240 2,560
A/Texas/50/12-N128A 1,280 10,240 2,560
A/Texas/50/12-A138S 480 5,120 1,280
A/Texas/50/12-R142G 640 7,680 1,920
A/Texas/50/12-N144S+N145S 1,280 10,240 3,840
A/Texas/50/12-N145S 480 5,120 1,920
A/Texas/50/12-F159S 240 3,840 3,840
A/Texas/50/12-N225D 640 7,680 2,560
A/Switzerland/9715293/13 60 1,280 2,560
HAI assays were completed using antisera isolated from ferrets 19 days post-infection or sheep 28 days post-infection. Data are representative of
three independent assays.This information is crucial for properly selecting viral strains
to be used in future vaccine formulations. In this report, we
demonstrate that sheep, ferrets, and humans exposed to the
2014–2015 A/Texas/50/2012 H3N2 vaccine strain mount Ab
responses that are targeted against HA antigenic site B. The ma-
jority of H3N2 viruses circulating during the 2014–2015 season
possessed mutations in antigenic site B (Figure 1A).
Our previous studies indicate that the specificity of human
H1N1 Ab responses is shaped by prior H1N1 exposures (Li
et al., 2013b; Linderman et al., 2014). We found that most human
H1N1 Ab responses are narrowly focused on epitopes that were
present in viral strains that circulated during each individual’s
childhood. It is unclear whether prior H3N2 exposures influence
the development of Ab responses to drifted H3N2 strains in a
similar manner. Our data indicate that most 21- to 50-year-olds
mount anti-A/Texas/50/2012 Abs against antigenic site B. It is
important to note that some individuals in our study (four of 32)
mounted anti-A/Texas/50/2012 Ab responses that were not
directed against antigenic site B (sera from these four individuals
had <2-fold change in HAI titer using the A/Texas/50/2012-WT
and A/Texas/50/2012-F159S strains). Current studies are under
way to investigate whether these four individuals have evidence
of unique H3N2 exposures.
The World Health Organization recently recommended that
the H3N2 component of the 2015–2016 seasonal vaccine should
be updated to include the A/Switzerland/9715293/2013 strain
(Anonymous, 2015). We note that this clade 3C.3a virus differs
in HA antigenic site B compared to clade 3C.2a viruses, which
predominated toward the end of the 2014–2015 Northern Hemi-
sphere influenza season (Figure 1). Clade 3C.2a viruses possess
a new predicted glycosylation site in antigenic site B due to
S159Y and K160T differences compared to A/Switzerland/
9715293/2013. The addition of a new glycosylation site on top
of the HA antigenic site B could potentially alter antigenicity
and Ab access to this region of HA. In our studies, sera iso-
lated from A/Switzerland/9715293/2013-infected animals re-
acted equally to the A/Switzerland/9715293/2013 strain and
our A/Texas/50/2012 mutant panel; however, additional studies
need to be completed to precisely define the specificity of Abs
elicited by A/Switzerland/9715293/2013 exposure.4 Cell Reports 12, 1–6, July 7, 2015 ª2015 The AuthorsTaken together, our data suggest that mutations in antigenic
site B of 2014–2015 H3N2 strains have led to a major antigenic
change. This antigenic change is likely responsible for the low
vaccine efficacy during the 2014–2015 season. Our studies sup-
port the World Health Organization’s decision to update the
H3N2 component of the 2015–2016 influenza vaccine.
EXPERIMENTAL PROCEDURES
HA Sequences
We obtained HA sequence data from the GISAID website http://platform.
gisaid.org/epi3/. Information related to the viral isolates used for these studies
is reported in Table S3.
Viruses
We obtained the A/Switzerland/9715293/2013 strain from the National Insti-
tute for Biological Standards and Control (NIBSC) in Hertfordshire, UK. We
created reverse-genetics-derived viruses that possessed the A/Texas/50/
2012 HA. Since we did not have the A/Texas/50/2012 strain when we initiated
these experiments, we extracted RNA from the A/Victoria/361/2011 strain and
cloned the HA of this virus into the pHW2000 reverse genetics plasmid. We
then usedQuickChange site-directedmutagenesis kits (Stratagene) to convert
the A/Victoria/361/2011HA sequence to the A/Texas/50/2012 HA sequence
(by adding T128N, G186V, S198P, S219F, N278K mutations). We then
introduced additional mutations from Table S1 into this A/Texas/50/2012
HA sequence. We rescued viruses that possessed the different mutated
A/Texas/50/2012 HAs after transfecting 293T/MDCK cell co-cultures with
the different HA plasmids and plasmids derived from A/Puerto Rico/8/1934
that encoded for the rest of the influenza genome. All viruses used for antigenic
analyses were propagated in 10-day-old fertilized chicken eggs. We used
Sanger sequencing to verify that additional mutations did not arise during viral
propagation.
Antisera
All sheep anti-sera used in this study were obtained from the National Insti-
tute for Biological Standards and Control (NIBSC) in Hertfordshire, UK.
Antisera were collected from sheep 28 days post-infection. Ferret antisera
used in this study were obtained from the Influenza Reagent Resource,
Influenza Division, WHO Collaborating Center for Surveillance, Epidemi-
ology and Control of Influenza, CDC, Atlanta, GA. Antisera were collected
from ferrets 19 days post-infection. Sera were also collected from humans
prior to vaccination and 21 days following vaccination with the 2014–2015
seasonal influenza vaccine. All studies involving the collection and analysis
of human sera were approved by the institutional review boards of the
Wistar Institute and Vaccine and Gene Therapy Institute of Florida. All
Table 3. Analyses of Sera Isolated from Humans Pre- and Post-
vaccination with the 2014–2015 Seasonal Influenza Vaccine that
Includes the A/Texas/50/2012 Vaccine Strain
Sample
ID
Age
(years)
Pre-vaccination Post-vaccination
A/Texas/
50/2012
A/Texas/50/
2012-F159S
A/Texas/
50/2012
A/Texas/50/
2012-F159S
01 21 240 40 160 40
02 23 640 240 320 160
03 24 240 80 240 80
04 25 240 80 240 80
05 26 80 <40 640 320
06 27 480 <40 320 <40
07 29 60 <40 120 40
08 30 60 40 80 40
09 30 <40 <40 640 320
10 30 320 240 640 480
11 31 320 80 320 120
12 31 40 <40 60 <40
13 31 <40 <40 40 <40
14 31 <40 <40 160 <40
15 31 40 <40 40 <40
16 34 480 60 640 80
17 35 480 80 320 120
18 35 160 80 160 160
19 35 320 240 640 320
20 35 160 <40 240 <40
21 36 60 <40 120 <40
22 38 <40 <40 120 <40
23 38 <40 <40 240 <40
24 39 240 80 320 80
25 41 320 240 320 240
26 44 <40 <40 80 40
27 44 40 <40 80 80
28 46 <40 <40 80 40
29 48 80 <40 160 40
30 48 <40 <40 60 <40
31 48 <40 <40 80 <40
32 50 80 40 160 80
Sera were collected from humans pre- and post-vaccination with the
2014–2015 seasonal influenza vaccine. HAI assays were completed
using A/Texas/50/2012 and A/Texas/50/2012 with the F159S HA muta-
tion. Data are representative of three independent assays.sera were treated with receptor-destroying enzyme (RDE) for 3 hr prior to
antigenic testing.
HAI Assays
HAI titrations were performed in 96-well round bottom plates. Sera were
serially diluted 2-fold and added to four agglutinating doses of virus in a total
volume of 100 ml. Next, 12.5 ml of a 2% (v/v) turkey red blood cell solution
was added. Agglutination was read out after incubating for 60 min at room
temperature. HAI titers were recorded as the inverse of the highest dilution
that inhibited hemagglutination of turkey red blood cells. Similar results were
obtained using guinea pig red blood cells.ELISA Assays
VLPs expressing A/Texas/50/2012-WT HA, A/Texas/50/2012-F159S HA, or
A/Port Chalmers/1/1973 HA were created. Codon-optimized sequences
were cloned into the pCMV-Sport6 plasmid. VLPs were rescued by transfect-
ing 293T cells with plasmids expressing HIV gag, A/Puerto Rico/8/1934 NA,
HAT (human airway trypsin-like protease), and each HA. VLPs isolated from
culture supernatants were concentrated using a 20% sucrose cushion and
resuspended in PBS. VLP amounts were normalized in ELISAs using the F49
mAb (Clontech) that binds to a conserved region of the H3 stalk. Goat anti-
ferret immunogloublin G (IgG) conjugated to horseradish peroxidase (Abcam)
was used to detect binding of A/Texas/50/2012 ferret antisera and goat anti-
mouse IgG conjugated to horseradish peroxidase (MP Biomedicals) was
used to detect the murine F49 mAb.
Neutralization Assays
In vitro neutralization assays were performed in 96-well flat bottom plates.
Sera were serially diluted and then added to 100 TCID50 units of A/Texas/
50/2012-WT or A/Texas/50/2012-F159S virus and incubated at room temper-
ature for 30min. The virus-sera mixtures were then incubated with MDCK cells
for 1 hr at 37C. Next, cells were washed, and then serum-free media with
TPCK-treated trypsin was added. We visually determined cytopathic end-
points 3 days later. Data are expressed as the inverse of the highest dilution
that caused neutralization.
Receptor Binding Assays
As previously described (Li et al., 2013a), turkey red blood cells were pre-
treated with different amounts of RDE (a neuraminidase) for 1 hr at 37C.
The red blood cells were washed with PBS and added (as 2% v/v solutions)
to four agglutinating doses of each virus (as determined using non-treated
red blood cells). After a 1-hr incubation, agglutination was measured. Viruses
with higher receptor binding avidities are able to bind to red blood cells that are
treated with high amounts of RDE (Li et al., 2013a).
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